



April 27, 2016

## **Arbutus to Participate in Upcoming Investor Conferences**

VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in the following upcoming investor conferences.

- | Bloom Burton & Co. Healthcare Investor Conference, May 2-3, 2016, Toronto
- | Bank of America Merrill Lynch 2016 Health Care Conference, May 10-12, 2016, Las Vegas

### **About Arbutus**

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

#### Contact Information

##### Investors

Adam Cutler

Senior Vice President, Corporate Affairs

Phone: 604.419.3200

Email: [acutler@arbutusbio.com](mailto:acutler@arbutusbio.com)

Helia Baradarani

Manager, Investor Relations

Phone: 604.419.3200

Email: [hbaradarani@arbutusbio.com](mailto:hbaradarani@arbutusbio.com)

##### Media

Please direct all media inquiries to: [media@arbutusbio.com](mailto:media@arbutusbio.com)